OncoBeta: Commercialized Radioisotope Cancer Therapy
Shannon D Brown III, CEO
"I’m a nine-time Basal-Cell Cancer survivor myself,” states Shannon D Brown III, CEO, OncoBeta® GmbH, during an intense discussion about the causes and repercussions of non-melanoma skin cancers. Sources have revealed that approximately five million fall ill to non-melanoma skin cancer every year and the rise in skin cancer incidence has been 300 percent since 1994. The personal trauma of experiencing one of the most underestimated ailments known probably inspired Brown to devise an unconventional resolve to mitigate the wrath of skin cancers. “We are one of the first healthcare service providers to have successfully developed and commercialized radioisotope therapy for the treatment of non-melanoma skin cancer,” states Brown, highlighting the uniqueness of his firm.
In the recent past, the Germany-based organization has garnered significant visibility for its flagship, the Rhenium-SCT® (Skin Cancer Therapy). The therapy utilizes the radioisotope, Rhenium-188, which penetrates to a depth of 2-3 mm into the skin tissue and reaches the tumor region, leaving the healthy cells below unaffected. The greatest advantage of the OncoBeta® therapy is its non-invasive, painless nature, and the ability to treat malignant cancers effortlessly. Unlike traditional cancer treatment approaches, patients adopting the OncoBeta® way can read books or flip television channels and websites during therapy, making it less frightening or troublesome and more of a pleasurable experience. Depending on the size of the tumor, most patients have been treated in just a single instance without recurrence and without the need for additional, post-surgery care, a norm with most traditional cancer therapies. Brown recalls an instance where the Rhenium-SCT healed a patient with around twenty-seven lesions in just one sitting, emphasizing the potential of OncoBeta’s therapy better.
Within a short span, the German firm’s unique therapy approach has been adopted by several reputed healthcare solution providers. Consulting dermatologists help patients identify skin areas marred by cancerous tissues, and work close with healthcare institutions in deciding the kind of therapy needed and subsequent adoption of OncoBeta’s solution.
OncoBeta® is one of the first healthcare service providers to have successfully developed and commercialized radioisotope therapy for the treatment of non-melanoma skin cancer
OncoBeta’s finesse in delivering cutting-edge solutions has made it the trusted partner of several firms worldwide and its clientele includes quite a few eminent names. In a short period of time, the company has garnered the reputation of being one of the ‘go-to’ vendors among healthcare professionals for the treatment of Basal- und Squamous- Cell Carcinomas. Brown testifies the capabilities of his firm better by recalling its collaboration with the Nuclear Medicine Department of the University of Bologna, based in Italy. Joining hands with OncoBeta® helped the educational institution foray together with their dermatology department for the first time and thus, deliver non-invasive treatment of non-melanoma skin cancer. The assistance of the German healthcare services provider supports the University of Pretoria & Steve Biko Academic Hospital, through one of its distributors Tautomer, render its services to individuals in South Africa, a nation known for one of the largest number of non-melanoma skin cancer victim populations per capita.
Brown believes that there still exists a large market segment that has been untapped and his team is putting its best foot forward to reach out to physicians and healthcare institutions across the globe. “The company intends to expand its presence to the rest of Europe, Africa, Australia, North and South America, as well as the Asian markets in the days to come,” concludes Brown, revealing a glimpse of the company’s roadmap. Several healthcare patrons have backed OncoBeta® with funds to propel cancer therapy efforts and the accomplishment has largely motivated the firm’s team.
This content is copyright protected
However, if you would like to share the information in this article, you may use the link below: